Calidi Biotherapeutics (CLDI) Company Report

Calidi Biotherapeutics reported a net loss of $5.2 million for the three months ended September 30, 2025, with net loss attributable to common stockholders of $10.8 million (including a non-cash charge for deemed dividend on warrants) and net loss per share of $2.21.
The company raised $6.9 million in gross proceeds from an underwritten public offering, contributing to a total of $23.0 million in gross proceeds from all offerings in 2025.
As of September 30, 2025, Calidi Biotherapeutics had approximately $10.4 million in cash and $0.2 million in restricted cash.
Operational highlights include presenting new preclinical data on CLD-401 at the Society of Immunotherapy for Cancer (SITC) annual meeting, establishing a new Scientific Advisory Board, and continuing to expand the RedTail platform capabilities.

Nov 13, 2025, 9:30 PM

Calidi Biotherapeutics, Inc. Divests Nova Cell, Inc. Subsidiary

CLDI

M&A

Calidi Biotherapeutics, Inc. entered into a Stock Repurchase Agreement and Material Purchase Agreement with its majority-owned subsidiary, Nova Cell, Inc., on October 27, 2025.
The company sold 22,500,000 shares of Nova Cell common stock, representing 100% of its ownership in Nova Cell, for a total purchase price of $6,000,000.
The purchase price was satisfied by a $1,214,864 cancellation of indebtedness and $4,785,136 in deferred consideration.
Following the transaction, Nova Cell is no longer a subsidiary of Calidi Biotherapeutics, Inc., and the company anticipates $0.5 million per year in general and administrative expense reductions.

Oct 31, 2025, 8:15 PM

Get instant answers from SEC filings, earnings calls & more

Calidi Biotherapeutics (CLDI)